Trial Profile
A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects Who Are Chronically Infected With Hepatitis C.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 625433 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Dec 2008 Checked against ClinicalTrials.gov.
- 18 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2007 New trial record.